Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085580 (
essential hypertension
)
14,686
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To evaluate the hypotensive efficacy of Verapamil alone and combined with diuretic, in the treatment of
essential hypertension
in elderly patients, we studied 54 patients, mean age 67.2 +/- 4.7 years, with
essential hypertension
, I-II WHO class. After a two-week wash-out from previous hypotensive therapies, patients were divided, at random, into three groups and, in double-blind conditions; they were treated as follows: the first group was treated with Verapamil (V) slow-release 240 mg/die, the second group with Chlorthalidone (C) 50 mg/die and the third group with the combination of Verapamil slow-release 240 mg/die and Chlorthalidone 50 mg/die (V + C). In the first group, the therapy (V) statistically reduced (p less than 0.001) either PAS or
PAD
values in supine position, (respectively -13 +/- 9 mmHg and -12 +/- 4 mmHg) and PAS-
PAD
values in upright position (respectively -16 +/- 3 mmHg and -10 +/- 3 mmHg). In the group treated with C, a statistically significant reduction (p less than 0.001) of PAS (-12 +/- 3 mmHg in supine position and -16 +/- 3 mmHg in upright position) and of
PAD
(-11 +/- 5 in supine and -9 +/- 4 mmHg in upright position). In the third group, V + C treatment induced a statistically bigger reduction of PAS and
PAD
(p less than 0.001) than that of the other two groups either in supine (-24 +/- 3 and -21 +/- 5 mmHg, respectively) or in upright position (-26 +/- 4 and -20 +/- 5 mmHg, respectively). Three patients interrupted the therapy for scarse compliance (I-II group).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:[Hypotensive efficacy of verapamil alone and in combination with a diuretic in the treatment of essential hypertension in geriatric patients]. 330
The aim of the HOT Study (Hypertension Optimal Treatment) was to determine the optimal diastolic blood pressure decrease and to assess the effect of the acetyl salicylic acid as a primary prevention on the cardiovascular morbidity and mortality in hypertensive patients. The HOT Study is an open, prospective, randomised, international trial with blinded end points. This study included 18,790 patients, 50 to 80 years old (mean 61.5 years) in 26 countries (1,574 patients in France) with a
primary hypertension
(100 < or =
PAD
< or = 115 mmHg). The patients were randomised in 3 target diastolic blood pressure: < or = 80 mmHg (n = 6,262), < or = 85 mmHg (n = 6,264), < or = 90 mmHg (n = 6,264). The felodipine LP, a long acting dihydropyridine, was selected as a first line therapy, other hypertension drugs combined if necessary. The lowest incidence of cardiovascular events was observed at a diastolic blood pressure level of 82.6 mmHg. There was no increased risk below this level even in the hypertensive patients with medical history of coronary heart disease or stroke. In the diabetic population, the diastolic blood pressure decrease from 90 to 80 reduced the incidence of the major cardiovascular events by 51%. The acetyl salicylic acid reduced the myocardial infarction risk in the blood pressure well-controlled population.
...
PMID:[Effect of intensive antihypertensive treatment and of aspirin in a low dose in the hypertensive. The HOT (Hypertension Optimal Treatment) study]. 1048 68